Biogen Idec Incorporated (BIIB)

Assess today's live Biogen Inc (BIIB) share price, performance and insights using our live NASDAQ: BIIB stock exchange data.

Analyse the historical data and Biogen Inc share price performance charts on this page. Our technical summary section provides analysis on Biogen share price buy/sell indicators using real-time data (or discuss the Biogen (BIIB) stock price today with other investors in the Biogen NASDAQ share price and sentiment chat forum).

Use the dropdown to select a relevant stock exchange for the current NASDAQ BIIB share price (ISIN: US09062X1037) to enhance your trading decisions with our free investment tools and resources.

What Is the Biogen Inc Share Price Today?
The Biogen share price today is 143.85.

What Is the Stock Symbol for Biogen Inc
The stock symbol (or 'ticker') for Biogen Idec Inc is "BIIB."

What Stock Exchange Does Biogen Inc Trade On?
Biogen Idec Inc is listed and trades on the NASDAQ stock exchange.

Is Biogen Inc a Good Stock to Buy?
Determining whether Biogen Idec Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.